Paul Bolno Sells 50,000 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) Stock

Wave Life Sciences Ltd. (NASDAQ:WVE) CEO Paul Bolno sold 50,000 shares of Wave Life Sciences stock in a transaction on Monday, November 25th. The stock was sold at an average price of $15.00, for a total transaction of $750,000.00. Following the completion of the transaction, the chief executive officer now owns 217,351 shares in the company, valued at $3,260,265. This trade represents a 18.70 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Paul Bolno also recently made the following trade(s):

• On Friday, November 15th, Paul Bolno sold 51,234 shares of Wave Life Sciences stock. The shares were sold at an average price of $14.32, for a total value of $733,670.88.
• On Wednesday, October 16th, Paul Bolno sold 90,474 shares of Wave Life Sciences stock. The stock was sold at an average price of $15.00, for a total value of $1,357,110.00.

Wave Life Sciences Price Performance

NASDAQ WVE opened at $14.99 on Friday. Wave Life Sciences Ltd. has a twelve month low of $3.50 and a twelve month high of $16.74. The company’s 50-day simple moving average is $12.30 and its 200 day simple moving average is $8.07.

Institutional Investors Weigh In On Wave Life Sciences

Large investors have recently modified their holdings of the stock. Privium Fund Management B.V. acquired a new stake in shares of Wave Life Sciences in the 3rd quarter valued at $400,000. Moody Aldrich Partners LLC boosted its position in Wave Life Sciences by 69.0% in the third quarter. Moody Aldrich Partners LLC now owns 303,062 shares of the company’s stock valued at $2,485,000 after buying an additional 123,703 shares in the last quarter. SG Americas Securities LLC bought a new stake in Wave Life Sciences during the second quarter worth about $668,000. Vanguard Group Inc. increased its holdings in shares of Wave Life Sciences by 39.7% during the first quarter. Vanguard Group Inc. now owns 1,834,090 shares of the company’s stock worth $11,316,000 after buying an additional 521,665 shares in the last quarter. Finally, Driehaus Capital Management LLC raised its stake in shares of Wave Life Sciences by 62.2% in the second quarter. Driehaus Capital Management LLC now owns 908,096 shares of the company’s stock valued at $4,531,000 after acquiring an additional 348,300 shares during the last quarter. 89.73% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

WVE has been the topic of a number of research analyst reports. Wells Fargo & Company raised their target price on Wave Life Sciences from $11.00 to $22.00 and gave the company an “overweight” rating in a report on Wednesday, October 16th. HC Wainwright restated a “buy” rating and issued a $22.00 price objective on shares of Wave Life Sciences in a research note on Wednesday, November 13th. Royal Bank of Canada upped their target price on shares of Wave Life Sciences from $7.00 to $15.00 and gave the company a “sector perform” rating in a research note on Monday, October 21st. Raymond James upgraded shares of Wave Life Sciences from an “outperform” rating to a “strong-buy” rating and raised their price target for the stock from $13.00 to $22.00 in a research report on Wednesday, October 16th. Finally, Mizuho upped their price objective on shares of Wave Life Sciences from $19.00 to $22.00 and gave the company an “outperform” rating in a research report on Thursday, November 21st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.22.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.